Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Celldex Therapeutics (CLDX)

Celldex Therapeutics (CLDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Celldex Therapeutics Initiates Phase 2 Study of Barzolvolimab for Atopic Dermatitis Treatment Quiver Quantitative, Inc. - Thu Dec 19, 5:24PM CST

Celldex Therapeutics initiates Phase 2 study of barzolvolimab for treating atopic dermatitis, currently enrolling patients.Quiver AI SummaryCelldex Therapeutics has launched a Phase 2 study of its monoclonal...

CLDX : 24.77 (-1.47%)
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis GlobeNewswire - Thu Dec 19, 7:01AM CST

CLDX : 24.77 (-1.47%)
Celldex Therapeutics Initiates Phase 1a Trial for Bispecific Antibody CDX-622 Targeting Chronic Inflammation Quiver Quantitative, Inc. - Wed Nov 20, 5:20PM CST

Celldex Therapeutics began Phase 1a study of CDX-622, targeting chronic inflammation through a bispecific antibody approach.Quiver AI SummaryCelldex Therapeutics, Inc. has announced the commencement of...

CLDX : 24.77 (-1.47%)
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases GlobeNewswire - Wed Nov 20, 7:01AM CST

CLDX : 24.77 (-1.47%)
Celldex Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire - Mon Nov 11, 3:01PM CST

CLDX : 24.77 (-1.47%)
Celldex: Q3 Earnings Snapshot AP - Wed Nov 6, 3:25PM CST

Celldex: Q3 Earnings Snapshot

CLDX : 24.77 (-1.47%)
Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update GlobeNewswire - Wed Nov 6, 3:01PM CST

CLDX : 24.77 (-1.47%)
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria GlobeNewswire - Sat Oct 26, 4:43PM CDT

CLDX : 24.77 (-1.47%)
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024 GlobeNewswire - Fri Oct 25, 7:01AM CDT

CLDX : 24.77 (-1.47%)
Bull & Bear - Bull market by Phive2015 via iStock
Can This Growth Stock Deliver 135% Upside in 2025? Barchart - Tue Oct 22, 8:00AM CDT

Positive clinical trial results have sparked hope for this biotech.

CLDX : 24.77 (-1.47%)
$SPX : 5,974.07 (+0.73%)

Barchart Exclusives

Why This Dividend Stock Just Scored a Rare Upgrade Barchart - 1 hour ago
Bristol Myers Squibb, a global biopharma company, has received a rare upgrade from Jefferies due to its promising pipeline and strategic partnerships. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot